The molecular physiology of nuclear retinoic acid receptors. From health to disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 8, 2011, Pages 1023-1031

  Duong, Vanessa ^a   Rochette Egly, Cécile ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Cancer; Homeostasis; Nuclear retinoic acid receptors; Transcription

Indexed keywords

CYCLIN DEPENDENT KINASE 7; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 6; MICRORNA; PHOSPHOPROTEIN; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR GAMMA; RETINOID; TUMOR NECROSIS FACTOR ALPHA;

ACNE; B LYMPHOCYTE; CANCER INHIBITION; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; CYTOTOXICITY; DNA BINDING; GENE MUTATION; GENE REARRANGEMENT; GRANULOPOIESIS; HEMATOPOIESIS; HEMATOPOIETIC CELL; HOMEOSTASIS AND REGULATION; IMMUNE RESPONSE; MACROPHAGE; MOLECULAR PHYSICS; MYELOID LEUKEMIA; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL; T LYMPHOCYTE; TRANSCRIPTION REGULATION; TUMOR GROWTH;

ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HOMEOSTASIS; HUMANS; MODELS, MOLECULAR; NEOPLASMS; PHOSPHORYLATION; PROTEIN CONFORMATION; RECEPTORS, RETINOIC ACID; SIGNAL TRANSDUCTION; SKIN DISEASES; TRANSCRIPTION, GENETIC;

EID: 79958254829     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.10.007     Document Type: Review

References (138)

1. Rochette-Egly C., Germain P. Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors. Nucl. Recept. Signal. 2009, 7:e005.
2. Germain P., Staels B., Dacquet C., Spedding M., Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 2006, 58:685-704.
3. Germain P., Chambon P., Eichele G., Evans R.M., Lazar M.A., Leid M., De Lera A.R., Lotan R., Mangelsdorf D.J., Gronemeyer H. International Union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol. Rev. 2006, 58:760-772.
4. Germain P., Chambon P., Eichele G., Evans R.M., Lazar M.A., Leid M., De Lera A.R., Lotan R., Mangelsdorf D.J., Gronemeyer H. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol. Rev. 2006, 58:712-725.
5. Delacroix L., Moutier E., Altobelli G., Legras S., Poch O., Choukrallah M.A., Bertin I., Jost B., Davidson I. Cell-specific interaction of retinoic acid receptors with target genes in mouse embryonic fibroblasts and embryonic stem cells. Mol. Cell. Biol. 2010, 30:231-244.
6. Bour G., Taneja R., Rochette-Egly C. Mouse embryocarcinoma F9 cells and retinoic acid. A model to study the molecular mechanisms of endodermal differentiation. Nuclear Receptors in Development 2006, vol. 16:211-253. Elsevier Press Inc. R. Raneja (Ed.).
7. Eifert C., Sangster-Guity N., Yu L.M., Chittur S.V., Perez A.V., Tine J.A., McCormick P.J. Global gene expression profiles associated with retinoic acid-induced differentiation of embryonal carcinoma cells. Mol. Reprod. Dev. 2006, 73:796-824.
8. Gudas L.J., Wagner J.A. Retinoids regulate stem cell differentiation. J. Cell. Physiol. 2010.
9. Mark M., Ghyselinck N.B., Chambon P. Function of retinoid nuclear receptors: lessons from genetic and pharmacological dissections of the retinoic acid signaling pathway during mouse embryogenesis. Annu. Rev. Pharmacol. Toxicol. 2006, 46:451-480.
10. Niederreither K., Dolle P. Retinoic acid in development: towards an integrated view. Nat. Rev. Genet. 2008, 9:541-553.
11. Dolle P. Developmental expression of retinoic acid receptors (RARs). Nucl. Recept. Signal. 2009, 7:e006.
12. Mark M., Ghyselinck N.B., Chambon P. Function of retinoic acid receptors during embryonic development. Nucl. Recept. Signal. 2009, 7:e002.
13. Su D., Gudas L.J. Gene expression profiling elucidates a specific role for RARgamma in the retinoic acid-induced differentiation of F9 teratocarcinoma stem cells. Biochem. Pharmacol. 2008, 75:1129-1160.
14. Metzger D., Indra A.K., Li M., Chapellier B., Calleja C., Ghyselinck N.B., Chambon P. Targeted conditional somatic mutagenesis in the mouse: temporally-controlled knock out of retinoid receptors in epidermal keratinocytes. Meth. Enzymol. 2003, 364:379-408.
15. Chapellier B., Mark M., Messaddeq N., Calleja C., Warot X., Brocard J., Gerard C., Li M., Metzger D., Ghyselinck N.B., Chambon P. Physiological and retinoid-induced proliferations of epidermis basal keratinocytes are differently controlled. EMBO J. 2002, 21:3402-3413.
16. Imai T., Jiang M., Kastner P., Chambon P., Metzger D. Selective ablation of retinoid X receptor alpha in hepatocytes impairs their lifespan and regenerative capacity. Proc. Natl Acad. Sci. USA 2001, 98:4581-4586.
17. Dzhagalov I., Chambon P., He Y.W. Regulation of CD8+ T lymphocyte effector function and macrophage inflammatory cytokine production by retinoic acid receptor gamma. J. Immunol. 2007, 178:2113-2121.
18. Germain P., Altucci L., Bourguet W., Rochette-Egly C., Gronemeyer H. Nuclear receptor superfamily: principles of signaling, in: J. Miyamoto, J. Burger (Eds.). Pure Appl. Chem. 2003, 75:1619-1664.
19. Rochette-Egly C. Dynamic combinatorial networks in nuclear receptor-mediated transcription. J. Biol. Chem. 2005, 280:32565-32568.
20. Laudet V., Gronemeyer H. Nuclear receptor factsbook 2001, Acedemic Press, London.
21. Martens J.H., Brinkman A.B., Simmer F., Francoijs K.J., Nebbioso A., Ferrara F., Altucci L., Stunnenberg H.G. PML-RARalpha/RXR alters the epigenetic landscape in acute promyelocytic leukemia. Cancer Cell 2010, 17:173-185.
22. Perissi V., Jepsen K., Glass C.K., Rosenfeld M.G. Deconstructing repression: evolving models of co-repressor action. Nat. Rev. Genet. 2010, 11:109-123.
23. Delva L., Bastie J.N., Rochette-Egly C., Kraiba R., Balitrand N., Despouy G., Chambon P., Chomienne C. Physical and functional interactions between cellular retinoic acid binding protein II and the retinoic acid-dependent nuclear complex. Mol. Cell. Biol. 1999, 19:7158-7167.
24. Budhu A.S., Noy N. Direct channeling of retinoic acid between cellular retinoic acid-binding protein II and retinoic acid receptor sensitizes mammary carcinoma cells to retinoic acid-induced growth arrest. Mol. Cell. Biol. 2002, 22:2632-2641.
25. le Maire A., Teyssier C., Erb C., Grimaldi M., Alvarez S., de Lera A.R., Balaguer P., Gronemeyer H., Royer C.A., Germain P., Bourguet W. A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor. Nat. Struct. Mol. Biol. 2010, 17:801-807.
26. Lefebvre P., Martin P.J., Flajollet S., Dedieu S., Billaut X., Lefebvre B. Transcriptional activities of retinoic acid receptors. Vitam. Horm. 2005, 70:199-264.
27. Rosenfeld M.G., Lunyak V.V., Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev. 2006, 20:1405-1428.
28. Alsayed Y., Uddin S., Mahmud N., Lekmine F., Kalvakolanu D.V., Minucci S., Bokoch G., Platanias L.C. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid. J. Biol. Chem. 2001, 276:4012-4019.
29. Gianni M., Parrella E., Raska I., Gaillard E., Nigro E.A., Gaudon C., Garattini E., Rochette-Egly C. P38MAPK-dependent phosphorylation and degradation of SRC-3/AIB1 and RARalpha-mediated transcription. EMBO J. 2006, 25:739-751.
30. Gianni M., Bauer A., Garattini E., Chambon P., Rochette-Egly C. Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-indced RARg degradation and transactivation. EMBO J. 2002, 21:3760-3769.
31. Bruck N., Vitoux D., Ferry C., Duong V., Bauer A., de The H., Rochette-Egly C. A coordinated phosphorylation cascade initiated by p38MAPK/MSK1 directs RARalpha to target promoters. EMBO J. 2009, 28:34-47.
32. Masia S., Alvarez S., de Lera A.R., Barettino D. Rapid, nongenomic actions of retinoic acid on phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor. Mol. Endocrinol. 2007, 21:2391-2402.
33. Dey N., De P.K., Wang M., Zhang H., Dobrota E.A., Robertson K.A., Durden D.L. CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation. Mol. Cell. Biol. 2007, 27:4179-4197.
34. Lalevee S., Ferry C., Rochette-Egly C. Phosphorylation control of nuclear receptors. Meth. Mol. Biol. 2010, 647:251-266.
35. Bastien J., Adam-Stitah S., Riedl T., Egly J.M., Chambon P., Rochette-Egly C. TFIIH interacts with the retinoic acid receptor gamma and phosphorylates its AF-1-activating domain through cdk7. J. Biol. Chem. 2000, 275:21896-21904.
36. Rochette-Egly C., Adam S., Rossignol M., Egly J.M., Chambon P. Stimulation of RAR alpha activation function AF-1 through binding to the general transcription factor TFIIH and phosphorylation by CDK7. Cell 1997, 90:97-107.
37. Bour G., Gaillard E., Bruck N., Lalevee S., Plassat J.L., Busso D., Samama J.P., Rochette-Egly C. Cyclin H binding to the RAR{alpha} activation function (AF)-2 domain directs phosphorylation of the AF-1 domain by cyclin-dependent kinase 7. Proc. Natl Acad. Sci. USA 2005, 102:16608-16613.
38. Gaillard E., Bruck N., Brelivet Y., Bour G., Lalevee S., Bauer A., Poch O., Moras D., Rochette-Egly C. Phosphorylation by protein kinase A potentiates retinoic acid receptor A activity by means of increasing interaction with and phosphorylation by cyclin H/cdk7. Proc. Natl Acad. Sci. USA 2006, 103:9548-9553.
39. Lalevee S., Bour G., Quinternet M., Samarut E., Kessler P., Vitorino M., Bruck N., Delsuc M.A., Vonesch J.L., Kieffer B., Rochette-Egly C. Vinexin{beta}, an atypical "sensor" of retinoic acid receptor gamma signaling: union and sequestration, separation, and phosphorylation. FASEB J. 2010.
40. Orkin S.H., Zon L.I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 2008, 132:631-644.
41. Orkin S.H., Zon L.I. SnapShot: hematopoiesis. Cell 2008, 132:712.
42. Ueno H., Weissman I.L. The origin and fate of yolk sac hematopoiesis: application of chimera analyses to developmental studies. Int. J. Dev. Biol. 2010, 54:1019-1031.
43. Wilson A., Laurenti E., Trumpp A. Balancing dormant and self-renewing hematopoietic stem cells. Curr. Opin. Genet. Dev. 2009, 19:461-468.
44. Kastner P., Chan S. Function of RARalpha during the maturation of neutrophils. Oncogene 2001, 20:7178-7185.
45. Collins S.J. The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia 2002, 16:1896-1905.
46. Purton L.E., Dworkin S., Olsen G.H., Walkley C.R., Fabb S.A., Collins S.J., Chambon P. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J. Exp. Med. 2006, 203:1283-1293.
47. Gordy C., Dzhagalov I., He Y.W. Regulation of CD8(+) T cell functions by RARgamma. Semin. Immunol. 2009, 21:2-7.
48. Wang S., Uchi H., Hayashida S., Urabe K., Moroi Y., Furue M. Differential expression of phosphorylated extracellular signal-regulated kinase 1/2, phosphorylated p38 mitogen-activated protein kinase and nuclear factor-kappaB p105/p50 in chronic inflammatory skin diseases. J. Dermatol. 2009, 36:534-540.
49. Vermeulen L., Berghe W.V., Beck I.M., De Bosscher K., Haegeman G. The versatile role of MSKs in transcriptional regulation. Trends Biochem. Sci. 2009, 34:311-318.
50. Na S.Y., Kang B.Y., Chung S.W., Han S.J., Ma X., Trinchieri G., Im S.Y., Lee J.W., Kim T.S. Retinoids inhibit interleukin-12 production in macrophages through physical associations of retinoid X receptor and NFkappaB. J. Biol. Chem. 1999, 274:7674-7680.
51. Kirchmeyer M., Koufany M., Sebillaud S., Netter P., Jouzeau J.Y., Bianchi A. All-trans retinoic acid suppresses interleukin-6 expression in interleukin-1-stimulated synovial fibroblasts by inhibition of ERK1/2 pathway independently of RAR activation. Arthritis Res. Ther. 2008, 10:R141.
52. Beck I.M., Berghe W.V., Gerlo S., Bougarne N., Vermeulen L., De Bosscher K., Haegeman G. Glucocorticoids and mitogen- and stress-activated protein kinase 1 inhibitors: possible partners in the combat against inflammation. Biochem. Pharmacol. 2009, 77:1194-1205.
53. Beck I.M., Vanden Berghe W., Vermeulen L., Yamamoto K.R., Haegeman G., De Bosscher K. Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases. Endocr. Rev. 2009, 30:830-882.
54. Zhou X., Kong N., Wang J., Fan H., Zou H., Horwitz D., Brand D., Liu Z., Zheng S.G. Cutting edge: all-trans retinoic acid sustains the stability and function of natural regulatory T cells in an inflammatory milieu. J. Immunol. 2010, 185:2675-2679.
55. Fatica A., Rosa A., Ballarino M., De Marchis M.L., Rasmussen K.D., Bozzoni I. Role of microRNAs in myeloid differentiation. Biochem. Soc. Trans. 2008, 36:1201-1205.
56. Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
57. Fazi F., Rosa A., Fatica A., Gelmetti V., De Marchis M.L., Nervi C., Bozzoni I. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell 2005, 123:819-831.
58. Saumet A., Vetter G., Bouttier M., Portales-Casamar E., Wasserman W.W., Maurin T., Mari B., Barbry P., Vallar L., Friederich E., Arar K., Cassinat B., Chomienne C., Lecellier C.H. Transcriptional repression of microRNA genes by PML-RARA increases expression of key cancer proteins in acute promyelocytic leukemia. Blood 2009, 113:412-421.
59. Geest C.R., Buitenhuis M., Laarhoven A.G., Bierings M.B., Bruin M.C., Vellenga E., Coffer P.J. p38 MAP kinase inhibits neutrophil development through phosphorylation of C/EBPalpha on serine 21. Stem Cells 2009, 27:2271-2282.
60. Geest C.R., Coffer P.J. MAPK signaling pathways in the regulation of hematopoiesis. J. Leukoc. Biol. 2009, 86:237-250.
61. Luo P., Wang A., Payne K.J., Peng H., Wang J.G., Parrish Y.K., Rogerio J.W., Triche T.J., He Q., Wu L. Intrinsic retinoic acid receptor alpha-cyclin-dependent kinase-activating kinase signaling involves coordination of the restricted proliferation and granulocytic differentiation of human hematopoietic stem cells. Stem. Cells 2007, 25:2628-2637.
62. Wang J., Barsky L.W., Shum C.H., Jong A., Weinberg K.I., Collins S.J., Triche T.J., Wu L. Retinoid-induced G1 arrest and differentiation activation are associated with a switch to cyclin-dependent kinase-activating kinase hypophosphorylation of retinoic acid receptor alpha. J. Biol. Chem. 2002, 277:43369-43376.
63. Labrecque J., Allan D., Chambon P., Iscove N.N., Lohnes D., Hoang T. Impaired granulocytic differentiation in vitro in hematopoietic cells lacking retinoic acid receptors alpha1 and gamma. Blood 1998, 92:607-615.
64. Wang S., Tricot G., Shi L., Xiong W., Zeng Z., Xu H., Zangari M., Barlogie B., Shaughnessy J.D., Zhan F. RARalpha2 expression is associated with disease progression and plays a crucial role in efficacy of ATRA treatment in myeloma. Blood 2009, 114:600-607.
65. Fisher G.J., Voorhees J.J. Molecular mechanisms of retinoid actions in skin. FASEB J. 1996, 10:1002-1013.
66. Fisher G.J., Talwar H.S., Xiao J.H., Datta S.C., Reddy A.P., Gaub M.P., Rochette-Egly C., Chambon P., Voorhees J.J. Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J. Biol. Chem. 1994, 269:20629-20635.
67. Fu X., Li H. Mesenchymal stem cells and skin wound repair and regeneration: possibilities and questions. Cell Tissue Res. 2009, 335:317-321.
68. van de Kerkhof P.C. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol. Ther. 2006, 19:252-263.
69. Menter A., Korman N.J., Elmets C.A., Feldman S.R., Gelfand J.M., Gordon K.B., Gottlieb A.B., Koo J.Y., Lebwohl M., Lim H.W., Van Voorhees A.S., Beutner K.R., Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J. Am. Acad. Dermatol. 2009, 61:451-485.
70. Roberson E.D., Bowcock A.M. Psoriasis genetics: breaking the barrier. Trends Genet. 2010, 26:415-423.
71. Lee D.D., Stojadinovic O., Krzyzanowska A., Vouthounis C., Blumenberg M., Tomic-Canic M. Retinoid-responsive transcriptional changes in epidermal keratinocytes. J. Cell. Physiol. 2009, 220:427-439.
72. Conti L., Cattaneo E. Neural stem cell systems: physiological players or in vitro entities?. Nat. Rev. Neurosci. 2010, 11:176-187.
73. Goncalves M.B., Boyle J., Webber D.J., Hall S., Minger S.L., Corcoran J.P. Timing of the retinoid-signalling pathway determines the expression of neuronal markers in neural progenitor cells. Dev. Biol. 2005, 278:60-70.
74. Goncalves M.B., Agudo M., Connor S., McMahon S., Minger S.L., Maden M., Corcoran J.P. Sequential RARbeta and alpha signalling in vivo can induce adult forebrain neural progenitor cells to differentiate into neurons through Shh and FGF signalling pathways. Dev. Biol. 2009, 326:305-313.
75. Kim M., Habiba A., Doherty J.M., Mills J.C., Mercer R.W., Huettner J.E. Regulation of mouse embryonic stem cell neural differentiation by retinoic acid. Dev. Biol. 2009, 328:456-471.
76. Bibel M., Richter J., Schrenk K., Tucker K.L., Staiger V., Korte M., Goetz M., Barde Y.A. Differentiation of mouse embryonic stem cells into a defined neuronal lineage. Nat. Neurosci. 2004, 7:1003-1009.
77. Stavridis M.P., Collins B.J., Storey K.G. Retinoic acid orchestrates fibroblast growth factor signalling to drive embryonic stem cell differentiation. Development 2010, 137:881-890.
78. Sutton M.A., Schuman E.M. Dendritic protein synthesis, synaptic plasticity, and memory. Cell 2006, 127:49-58.
79. Aoto J., Nam C.I., Poon M.M., Ting P., Chen L. Synaptic signaling by all-trans retinoic acid in homeostatic synaptic plasticity. Neuron 2008, 60:308-320.
80. Chen N., Onisko B., Napoli J.L. The nuclear transcription factor RARalpha associates with neuronal RNA granules and suppresses translation. J. Biol. Chem. 2008, 283:20841-20847.
81. Maghsoodi B., Poon M.M., Nam C.I., Aoto J., Ting P., Chen L. Retinoic acid regulates RARalpha-mediated control of translation in dendritic RNA granules during homeostatic synaptic plasticity. Proc. Natl Acad. Sci. USA 2008, 105:16015-16020.
82. Poon M.M., Chen L. Retinoic acid-gated sequence-specific translational control by RARalpha. Proc. Natl Acad. Sci. USA 2008, 105:20303-20308.
83. Misner D.L., Jacobs S., Shimizu Y., de Urquiza A.M., Solomin L., Perlmann T., De Luca L.M., Stevens C.F., Evans R.M. Vitamin A deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc. Natl Acad. Sci. USA 2001, 98:11714-11719.
84. Lane M.A., Bailey S.J. Role of retinoid signalling in the adult brain. Prog. Neurobiol. 2005, 75:275-293.
85. Shudo K., Fukasawa H., Nakagomi M., Yamagata N. Towards retinoid therapy for Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:302-311.
86. Fahrenholz F., Tippmann F., Endres K. Retinoids as a perspective in treatment of Alzheimer's disease. Neurodegener. Dis. 2010, 7:190-192.
87. Samad T.A., Krezel W., Chambon P., Borrelli E. Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proc. Natl Acad. Sci. USA 1997, 94:14349-14354.
88. Sell S. Leukemia: stem cells, maturation arrest, and differentiation therapy. Stem Cell Rev. 2005, 1:197-205.
89. Pandolfi P.P. Oncogenes and tumor suppressors in the molecular pathogenesis of acute promyelocytic leukemia. Hum. Mol. Genet. 2001, 10:769-775.
90. Catalano A., Dawson M.A., Somana K., Opat S., Schwarer A., Campbell L.J., Iland H. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. Blood 2007, 110:4073-4076.
91. Buijs A., Bruin M. Fusion of FIP1L1 and RARA as a result of a novel t(4;17)(q12;q21) in a case of juvenile myelomonocytic leukemia. Leukemia 2007, 21:1104-1108.
92. de The H., Chomienne C., Lanotte M., Degos L., Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990, 347:558-561.
93. Zeisig B.B., Kwok C., Zelent A., Shankaranarayanan P., Gronemeyer H., Dong S., So C.W. Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell 2007, 12:36-51.
94. Zhu J., Nasr R., Peres L., Riaucoux-Lormiere F., Honore N., Berthier C., Kamashev D., Zhou J., Vitoux D., Lavau C., de The H. RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 2007, 12:23-35.
95. Di Croce L., Raker V.A., Corsaro M., Fazi F., Fanelli M., Faretta M., Fuks F., Lo Coco F., Kouzarides T., Nervi C., Minucci S., Pelicci P.G. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 2002, 295:1079-1082.
96. Altucci L., Gronemeyer H. The promise of retinoids to fight against cancer. Nat. Rev. Cancer 2001, 1:181-193.
97. Minucci S., Nervi C., Lo Coco F., Pelicci P.G. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?. Oncogene 2001, 20:3110-3115.
98. Petrie K., Zelent A., Waxman S. Differentiation therapy of acute myeloid leukemia: past, present and future. Curr. Opin. Hematol. 2009, 16:84-91.
99. Cote S., Rosenauer A., Bianchini A., Seiter K., Vandewiele J., Nervi C., Miller W.H. Response to histone deacetylase inhibition of novel PML/RARalpha mutants detected in retinoic acid-resistant APL cells. Blood 2002, 100:2586-2596.
100. Schachter-Tokarz E., Kelaidi C., Cassinat B., Chomienne C., Gardin C., Raffoux E., Dombret H., Fenaux P., Gallagher R. PML-RARalpha ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL. Leukemia 2010, 24:473-476.
101. Higuchi T., Kizaki M., Omine M. Induction of differentiation of retinoic acid-resistant acute promyelocytic leukemia cells by the combination of all-trans retinoic acid and granulocyte colony-stimulating factor. Leuk. Res. 2004, 28:525-532.
102. Glasow A., Prodromou N., Xu K., von Lindern M., Zelent A. Retinoids and myelomonocytic growth factors cooperatively activate RARA and induce human myeloid leukemia cell differentiation via MAP kinase pathways. Blood 2005, 105:341-349.
103. Ito K., Bernardi R., Morotti A., Matsuoka S., Saglio G., Ikeda Y., Rosenblatt J., Avigan D.E., Teruya-Feldstein J., Pandolfi P.P. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008, 453:1072-1078.
104. Tatham M.H., Geoffroy M.C., Shen L., Plechanovova A., Hattersley N., Jaffray E.G., Palvimo J.J., Hay R.T. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. Nat. Cell Biol. 2008, 10:538-546.
105. Lallemand-Breitenbach V., Jeanne M., Benhenda S., Nasr R., Lei M., Peres L., Zhou J., Zhu J., Raught B., de The H. Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat. Cell Biol. 2008, 10:547-555.
106. Nasr R., Guillemin M.C., Ferhi O., Soilihi H., Peres L., Berthier C., Rousselot P., Robledo-Sarmiento M., Lallemand-Breitenbach V., Gourmel B., Vitoux D., Pandolfi P.P., Rochette-Egly C., Zhu J., de The H. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat. Med. 2008, 14:1333-1342.
107. Nasr R., Lallemand-Breitenbach V., Zhu J., Guillemin M.C., de The H. Therapy-induced PML/RARA proteolysis and acute promyelocytic leukemia cure. Clin. Cancer Res. 2009, 15:6321-6326.
108. Chen C.F., Goyette P., Lohnes D. RARgamma acts as a tumor suppressor in mouse keratinocytes. Oncogene 2004, 23:5350-5359.
109. Klaassen I., Brakenhoff R.H., Smeets S.J., Snow G.B., Braakhuis B.J. Expression of retinoic acid receptor gamma correlates with retinoic acid sensitivity and metabolism in head and neck squamous cell carcinoma cell lines. Int. J. Cancer 2001, 92:661-665.
110. Wang Z., Boudjelal M., Kang S., Voorhees J.J., Fisher G.J. Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment. Nat. Med. 1999, 5:418-422.
111. Boudjelal M., Wang Z., Voorhees J.J., Fisher G.J. Ubiquitin/proteasome pathway regulates levels of retinoic acid receptor gamma and retinoid X receptor alpha in human keratinocytes. Cancer Res. 2000, 60:2247-2252.
112. Picard E., Seguin C., Monhoven N., Rochette-Egly C., Siat J., Borrelly J., Martinet Y., Martinet N., Vignaud J.M. Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J. Natl Cancer Inst. 1999, 91:1059-1066.
113. Suh Y.A., Lee H.Y., Virmani A., Wong J., Mann K.K., Miller W.H., Gazdar A., Kurie J.M. Loss of retinoic acid receptor beta gene expression is linked to aberrant histone H3 acetylation in lung cancer cell lines. Cancer Res. 2002, 62:3945-3949.
114. Zhang Z., Joh K., Yatsuki H., Zhao W., Soejima H., Higashimoto K., Noguchi M., Yokoyama M., Iwasaka T., Mukai T. Retinoic acid receptor beta2 is epigenetically silenced either by DNA methylation or repressive histone modifications at the promoter in cervical cancer cells. Cancer Lett. 2007, 247:318-327.
115. Widschwendter M., Berger J., Hermann M., Muller H.M., Amberger A., Zeschnigk M., Widschwendter A., Abendstein B., Zeimet A.G., Daxenbichler G., Marth C. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J. Natl Cancer Inst. 2000, 92:826-832.
116. Houle B., Rochette-Egly C., Bradley W.E. Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells. Proc. Natl Acad. Sci. USA 1993, 90:985-989.
117. Farias E.F., Petrie K., Leibovitch B., Murtagh J., Chornet M.B., Schenk T., Zelent A., Waxman S. Interference with Sin3 function induces epigenetic reprogramming and differentiation in breast cancer cells. Proc. Natl Acad. Sci. USA 2010, 107:11811-11816.
118. Cras A., Darsin-Bettinger D., Balitrand N., Cassinat B., Soulie A., Toubert M.E., Delva L., Chomienne C. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene 2007, 26:4018-4024.
119. Parrado A., Despouy G., Kraiba R., Le Pogam C., Dupas S., Choquette M., Robledo M., Larghero J., Bui H., Le Gall I., Rochette-Egly C., Chomienne C., Padua R.A. Retinoic acid receptor alpha1 variants, RARalpha1DeltaB and RARalpha1DeltaBC, define a new class of nuclear receptor isoforms. Nucleic Acids Res. 2001, 29:4901-4908.
120. Yan T.D., Wu H., Zhang H.P., Lu N., Ye P., Yu F.H., Zhou H., Li W.G., Cao X., Lin Y.Y., He J.Y., Gao W.W., Zhao Y., Xie L., Chen J.B., Zhang X.K., Zeng J.Z. Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma. Cancer Res. 2010, 70:2285-2295.
121. Franke T.F. PI3K/Akt: getting it right matters. Oncogene 2008, 27:6473-6488.
122. Khetchoumian K., Teletin M., Tisserand J., Mark M., Herquel B., Ignat M., Zucman-Rossi J., Cammas F., Lerouge T., Thibault C., Metzger D., Chambon P., Losson R. Loss of Trim24 (Tif1alpha) gene function confers oncogenic activity to retinoic acid receptor alpha. Nat. Genet. 2007, 39:1500-1506.
123. Hua S., Kittler R., White K.P. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 2009, 137:1259-1271.
124. Ross-Innes C.S., Stark R., Holmes K.A., Schmidt D., Spyrou C., Russell R., Massie C.E., Vowler S.L., Eldridge M., Carroll J.S. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev. 2010, 24:171-182.
125. Schug T.T., Berry D.C., Shaw N.S., Travis S.N., Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007, 129:723-733.
126. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
127. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
128. Moasser M.M. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 2007, 26:6469-6487.
129. Hynes N.E., MacDonald G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 2009, 21:177-184.
130. Tari A.M., Lim S.J., Hung M.C., Esteva F.J., Lopez-Berestein G. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells. Oncogene 2002, 21:5224-5232.
131. Srinivas H., Juroske D.M., Kalyankrishna S., Cody D.D., Price R.E., Xu X.C., Narayanan R., Weigel N.L., Kurie J.M. c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol. Cell. Biol. 2005, 25:1054-1069.
132. Srinivas H., Xia D., Moore N.L., Uray I.P., Kim H., Ma L., Weigel N.L., Brown P.H., Kurie J.M. Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem. J. 2006, 395:653-662.
133. Keriel A., Stary A., Sarasin A., Rochette-Egly C., Egly J.M. XPD mutations prevent TFIIH-dependent transactivation by nuclear receptors and phosphorylation of RARalpha. Cell 2002, 109:125-135.
134. Visvader J.E. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Genes Dev. 2009, 23:2563-2577.
135. Berry D.C., Noy N. All-trans-retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferation-activated receptor beta/delta and retinoic acid receptor. Mol. Cell. Biol. 2009, 29:3286-3296.
136. Indra A.K., Castaneda E., Antal M.C., Jiang M., Messaddeq N., Meng X., Loehr C.V., Gariglio P., Kato S., Wahli W., Desvergne B., Metzger D., Chambon P. Malignant transformation of DMBA/TPA-induced papillomas and nevi in the skin of mice selectively lacking retinoid-X-receptor alpha in epidermal keratinocytes. J. Invest. Dermatol. 2007, 127:1250-1260.
137. Martinet N., Alla F., Farre G., Labib T., Drouot H., Vidili R., Picard E., Gaube M.P., Le Faou D., Siat J., Borelly J., Vermylen P., Bazarbachi T., Vignaud J.M., Martinet Y. Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions. Cancer Res. 2000, 60:2869-2875.
138. Matsushima-Nishiwaki R., Okuno M., Adachi S., Sano T., Akita K., Moriwaki H., Friedman S.L., Kojima S. Phosphorylation of retinoid X receptor alpha at serine 260 impairs its metabolism and function in human hepatocellular carcinoma. Cancer Res. 2001, 61:7675-7682.